Equity
€140,616 ▲ 0.1%
Osteolab paid out €100,000 in dividends. That is 100% of the 2025 profit.
Osteolab
Lifetime
8 annual accounts with figures on one time axispeak €177,527 (2025)
€177,527▲ 11.2%
peak €100,116 (2025)
€100,116▲ 19.5%
peak €140,616 (2025)
€140,616▲ 0.1%
€307,363▲ 4.5%
Board1 name since 2018
-
Documentsfilings and deeds
26-05-202666 days before the deadline
2025micro format
Dividend €100,000Cash from €3,538 to €6,503
Key points
from the 2025 annual accountsChecked score
92
Excellent
Financially stronger than 33% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,185 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%lowest value
01-2025: < 0.1%● unchanged vs 12-2024lowest value
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: 0.1%▲ +0.1 percentage points vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026highest value
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Liquidity: current ratio 1.07, cash €6,503
lowers risk
Sector: Human health activities (NACE 86)
Size: total assets €447,979
Figures for financial year 2025 (filed on 02-06-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 27% of them on solvency, 8% on liquidity, 56% on profitability and 39% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 26,972 companies had the same profile as Osteolab has now. Each dot stands for 68 companies, two years later.
94.9%
were still trading
3.4%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of Osteolab itself is lower: 0.1% within 12 months. It rests on far more data about Osteolab than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,972 companies, not a prediction for Osteolab. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €12,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.07 (0.92 in 2024), below the usual 1.5. Short-term debt is 34.2% and cash 1.5% of total assets. 68.6% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 26-05-2026, 66 days ahead of the deadline.
NBB · 8 filingsDeviation from the deadline
2025
66 days early
2024
9 days early
2023
26 days early
2022
7 days early
2021
13 days early
2020
4 days early
2019
41 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 12 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 18 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0687836007
Change of role: EgwinPonette, from manager to director
Director discharge: EgwinPonette · General meeting of 13-12-2023 · Gazette deed
Incorporation
published on 15-01-2018 · Gazette deed
First establishment
Otegemstraat 198, Zwevegem
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Osteolab Zwevegem | €447,979 | €177,527 | 31.4% | - |
| Dr. Mieke Lauwers, gynaecologe Lennik | €458,288 | €181,129 | 38.6% | - |
| TUDOR MED Genk | €445,540 | €178,791 | 61.7% | - |
| DOCTEUR CLEMENCE MUKASHEMA Braine-l'Alleud | €460,546 | €180,432 | 24.2% | - |
| DR. VANTHUYNE STEVE, ANESTHESIST Merelbeke-Melle | €425,256 | €169,898 | 79.1% | - |
| DR. INNEKE BERTRAND Alken | €487,335 | €170,361 | 45.2% | - |
| Acasandrei Ciprian Cardiologie Arlon | €406,391 | €190,273 | 57.4% | - |
These companies have the same main activity as Osteolab: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €406,000 and €487,000, founded between 2017 and 2018.
Official details
Source: KBO- Status
- Active since 11-01-2018Normal situation
- Activity
- Specialist medical practiceNACE 86220and 1 other
- Establishment unit
- 2.272.260.2368550 Zwevegem, since 11-01-2018
- Financial year end
- 31 December
- Peppol
- Reachable since 12-02-2025
Annual accounts 2025
- €447,979▲ 3.1%
- Filing
- Filed on 26-05-2026, 66 days before the end of the filing period
Insights on Osteolab
Osteolab files the micro format. That format states no turnover. The gross margin rose from €60,329 in 2018 to €177,527 in 2025.
The balance sheet grew most in 2019 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Osteolab
- What is the company number of Osteolab?
- The company number of Osteolab is 0687.836.007. The VAT number is the same number with BE in front: BE 0687.836.007.
- Where is Osteolab based?
- The registered office is at Otegemstraat 198, 8550 Zwevegem.Company details
- What does Osteolab do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of Osteolab?
- Osteolab is a private limited company (BV).
- When was Osteolab founded?
- Osteolab was founded on 11-01-2018.
- Is Osteolab still active?
- Yes, Osteolab is an active enterprise in the KBO register.
- What is the turnover of Osteolab?
- The turnover in financial year 2025 is ≈ €330,000. This figure is estimated from the gross margin of €177,527 and 41 comparable companies (NACE 86220). It probably lies between €280,000 and €440,000.Financials
- Is Osteolab profitable?
- In financial year 2025, Osteolab made a profit of €100,116.
- Where can I find the annual accounts of Osteolab?
- Osteolab filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Osteolab due?
- Osteolab must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.